Prof. Nat Lenzo
/content/dam/asset-migration/headshots/au-doctor-headshots/AU_Theranostics_Headshot_GA_Prof Nat Lenzo.jpg

Prof Nat Lenzo

Prof Nat Lenzo
BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD, Nuclear Medicine and Internal Medicine Physician

Languages spoken

English, Italian

Expert in

Theranostics, molecular imaging and translational research



Hurstville (Oncology)
Hurstville (Oncology)

Waratah Private Hospital, Level 6, 31 Dora Street, Hurstville, NSW, 2220

-33.96416762029818, 151.1004695691989
Murdoch (Oncology)
Murdoch (Oncology)

100 Murdoch Drive, Murdoch WA 6150 (access via St John of God Murdoch Hospital, Gate 3

-32.067130818740424, 115.84572533810733

Specialises in

Prostate cancer
Condition/Cancer/Prostate Cancer
Neuroendocrine tumours
Thyroid cancer including anaplastic


Lutetium-177 PSMA therapy
Service/Cancer/Theranostics/Lutetium PSMA Therapy

Special clinical interests in theranostics, molecular imaging and translational research.

Nat graduated in medicine from the University of Western Australia and then completed a fellowship in nuclear medicine at the University of Michigan. Apart from undergraduate science, research and medical degrees, he also holds masters degrees in medicine, oncology, health service management and business administration, and is currently completing an online masters in molecular oncology with the European School of Medical Oncology.

From 2001 – 2006, Nat was the inaugural head of the Western Australian PET/cyclotron service based at Sir Charles Gairdner Hospital. He has also held head of department positions in Nuclear Medicine and Internal Medicine at Royal Perth Hospital and Fremantle Hospital.

Currently, Nat is an an adjunct clinical professor in Medicine at Curtin University and Notre Dame University Australia. He also works consultant nuclear physician and acute medicine physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch.

With a strong track record in developing clinical and research services in the public and private sectors, Nat’s research interests are in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. He is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and a co-author on over 50 peer reviewed publications, predominantly in the areas of molecular imaging and therapy in neuroscience and oncology.

In 2015, Nat founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of group clinical director. He is committed to expanding the field of theranostics with GenesisCare in Australia and overseas.